A care model led by advanced practice nurses was feasible in providing supportive care and linking providers through ...

Maria C. Velez, MD, shared that teamwork between pediatric and adult care teams can make the transition of care smoother for ...

Experts outline AE risks—including ICANS, CRS, HLH—as T-cell engager use expands, highlighting the crucial role of nurses and ...

BC, explains how educating patients about the Breast Cancer Index can support informed endocrine therapy decisions.

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says ...

Ronald Bleday, MD, explained that a model to reduce opioid use in patients after colorectal surgery relies on nurses familiar ...

The FDA has granted accelerated approval to zongertinib (Hernexeos) for use in patients with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) with HER2 (ERBB2) tyrosine kinase ...

The FDA has granted accelerated approval to dordaviprone for use in adult and pediatric patients with H3 K27M-mutated diffuse midline glioma.

Panelists discuss how dose modifications for ALK inhibitors can significantly improve quality-of-life issues such as brain fog and weight gain while maintaining disease control, emphasizing the ...

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient quality of life, while emphasizing that temporary treatment holds due to ...

This Rx Road Map outlines the most important information nurses should know when treating patients with astrocytoma or oligodendroglioma with vorasidenib.

Treatment decisions for older adults after CDK4/6 inhibitors should be tailored, explained Courtney Moore, APRN, FNP-C, OCN.